Discrimination between HER2-low and HER2-zero cancers is critical, as lower agreement and accuracy among pathologists have been noted when interpreting scanned slides of HER2 1+ and HER2 0 scores in biopsies (Fernandez et al., 2022). This evidence concerns the gene ERBB2 and cancer.